Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novo Nordisk's Ozempic approved in E.U.

Feb. 12, 2018

FDA grants orphan drug designation to Xeris' ready-to-use, liquid-stable glucagon

Feb. 9, 2018

Significant reductions in LDL-cholesterol seen with MGL-3196 in phase II tiral

Feb. 9, 2018

Vifor prepares to begin phase I trial of oral ferroportin inhibitor VIT-2763

Feb. 9, 2018

Jupiter Orphan Therapeutics preparing INDs for Jotrol

Feb. 6, 2018

Ozempic and Fiasp launched in the U.S.

Feb. 6, 2018

FDA grants orphan drug designation to Hanmi's LAPS glucagon analogue

Feb. 5, 2018

Crinetics Pharmaceuticals identifies new somatostatin SST2 receptor agonists

Feb. 2, 2018

AVROBIO completes series B financing to advance gene therapy pipeline for lysosomal storage disorder

Feb. 2, 2018

FDA grants priority review to patisiran NDA in hereditary ATTR amyloidosis

Feb. 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...